RAPT Therapeutics (RAPT) News Today $1.20 +0.01 (+0.84%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 9, 2025 | globenewswire.comRapt Therapeutics appoints Lyons-Williams as chair of board of directorsJanuary 7, 2025 | markets.businessinsider.comRAPT Therapeutics Announces Leadership Changes and RealignmentJanuary 7, 2025 | msn.comRAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of DirectorsJanuary 6, 2025 | markets.businessinsider.comRAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of DirectorsJanuary 6, 2025 | globenewswire.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of "Hold" from AnalystsShares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) have been assigned an average recommendation of "Hold" from the thirteen research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have issued a holdJanuary 4, 2025 | marketbeat.comShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Grows By 25.5%RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,720,000 shares, an increase of 25.5% from the November 30th total of 1,370,000 shares. Based on an average trading volume of 2,800,000 shares, the days-to-cover ratio is presently 0.6 days.December 30, 2024 | marketbeat.comNotable analyst calls this week: FREYR Battery, Apple and ServiceNow among top picksDecember 28, 2024 | msn.comRAPT upgraded at H.C. Wainwright on China licensing dealDecember 26, 2024 | msn.comPositive Report for RAPT Therapeutics (RAPT) from H.C. WainwrightDecember 26, 2024 | markets.businessinsider.comHC Wainwright & Co. Upgrades RAPT Therapeutics (RAPT)December 26, 2024 | msn.comRapt Therapeutics upgraded to Buy from Neutral at H.C. WainwrightDecember 26, 2024 | markets.businessinsider.comRAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Buy" at HC WainwrightHC Wainwright upgraded RAPT Therapeutics from a "neutral" rating to a "buy" rating and set a $10.00 price target on the stock in a research report on Thursday.December 26, 2024 | marketbeat.comCautious Hold Recommendation for RAPT Therapeutics Amid Strategic Acquisition and Market UncertaintiesDecember 25, 2024 | markets.businessinsider.comRAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreementDecember 25, 2024 | msn.comRAPT Therapeutics stock rises following licensing deal with JemincareDecember 24, 2024 | in.investing.comRapt Therapeutics price target raised to $6 from $4 at Wells FargoDecember 24, 2024 | markets.businessinsider.comRAPT rockets 180% on licensing deal, $150M private placement (update)December 24, 2024 | msn.comPeninsula drugmaker lands $150 million, food allergy drug to fill pipeline holeDecember 24, 2024 | bizjournals.comRAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE AntibodyDecember 23, 2024 | markets.businessinsider.comRAPT Therapeutics Announces $150 Million Private PlacementDecember 23, 2024 | globenewswire.comRAPT Therapeutics: Hold Rating Amid Strategic Uncertainties and Financial ResilienceNovember 26, 2024 | markets.businessinsider.comRAPT Therapeutics Reprices Underwater Employee Stock OptionsNovember 16, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for RAPT Issued By Leerink PartnrsRAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Equities researchers at Leerink Partnrs boosted their FY2024 EPS estimates for shares of RAPT Therapeutics in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($2.3November 15, 2024 | marketbeat.comRAPT Therapeutics Reports Improved Q3 2024 ResultsNovember 14, 2024 | markets.businessinsider.comWhat is Leerink Partnrs' Estimate for RAPT FY2024 Earnings?RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of RAPT Therapeutics in a research report issued to clients and investors on Monday, November 11th. Leerink Partnrs analyst T. Smith now expects thaNovember 14, 2024 | marketbeat.comRAPT Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comRAPT Therapeutics: Strategic Shift to Next-Gen Compounds Boosts Buy Rating Despite Program TerminationNovember 13, 2024 | markets.businessinsider.comRAPT Therapeutics (NASDAQ:RAPT) Receives "Hold" Rating from Stifel NicolausStifel Nicolaus reiterated a "hold" rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday.November 13, 2024 | marketbeat.comWells Fargo & Company Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock PriceWells Fargo & Company decreased their price target on RAPT Therapeutics from $17.00 to $4.00 and set an "overweight" rating on the stock in a research note on Tuesday.November 12, 2024 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Receives "Neutral" Rating from HC WainwrightHC Wainwright reissued a "neutral" rating on shares of RAPT Therapeutics in a research report on Tuesday.November 12, 2024 | marketbeat.comBased on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver InjuryNovember 12, 2024 | markets.businessinsider.comJP Morgan Downgrades RAPT Therapeutics (RAPT)November 12, 2024 | msn.comRAPT scraps zelnecirnon program, stock plunges 46% (update)November 11, 2024 | seekingalpha.comRapt Therapeutics Stops Development of Asthma, Atopic Dermatitis Drug Candidate After Reaction Sidelines TrialsNovember 11, 2024 | marketwatch.comRAPT Shares Fall to All-Time Low After Zelnecirnon Programs TerminatedNovember 11, 2024 | marketwatch.comRAPT scraps zelnecirnon program, stock plunges 44%November 11, 2024 | msn.comJPMorgan cuts Rapt Therapeutics to Underweight after zelnecirnon discontinuedNovember 11, 2024 | markets.businessinsider.comRapt Therapeutics model under review at Stifel after zelnecirnon discontinuedNovember 11, 2024 | markets.businessinsider.comRAPT Therapeutics shares tumble by 48% after zelnecirnon programme cullNovember 11, 2024 | finance.yahoo.comRAPT Therapeutics (NASDAQ:RAPT) Lowered to "Underweight" Rating by JPMorgan Chase & Co.JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a "neutral" rating to an "underweight" rating in a report on Monday.November 11, 2024 | marketbeat.comRapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver InjuryNovember 11, 2024 | benzinga.comCompanies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite RiskyNovember 9, 2024 | finance.yahoo.comPromising Risk-Reward Scenario for RAPT Therapeutics: A Buy Rating Amid Clinical Uncertainties and Valuation ConsiderationsNovember 6, 2024 | markets.businessinsider.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of "Hold" by BrokeragesRAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are currently covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation and one has givenOctober 21, 2024 | marketbeat.comPoint72 Asset Management L.P. Buys 706,900 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)Point72 Asset Management L.P. increased its stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 176,725.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 707,300 shares of the company's stock after purcOctober 4, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Bought by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC grew its position in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 826.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 295,241 shares of the company's stockOctober 3, 2024 | marketbeat.comRAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy NowSeptember 29, 2024 | finance.yahoo.comGastric Cancer Pipeline Insights, Treatment Drugs, Clinical Trials and Companies 2024September 27, 2024 | theglobeandmail.comRAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite UnprofitabilitySeptember 25, 2024 | msn.com Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPT Media Mentions By Week RAPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPT News Sentiment▼0.440.57▲Average Medical News Sentiment RAPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPT Articles This Week▼13▲RAPT Articles Average Week Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADC Therapeutics News Today Bright Minds Biosciences News Today Vaxart News Today Nkarta News Today Protalix BioTherapeutics News Today Greenwich LifeSciences News Today Actuate Therapeutics News Today Puma Biotechnology News Today Cidara Therapeutics News Today Checkpoint Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
